Perfluorocarbon products: SYBD has four issued U.S. (5,674,913; 5,824,703; 5,840,767; 6,167,887) and two Australian (690277; 722417) perfluorocarbon patents that protect the use of perfluorocarbons of interest to the company as gas transport agents in blood substitutes and liquid ventil-ation. Additionally, through an exclusive supply agreement with our perfluorocarbon supplier, SYBD has exclusive rights to eight perfluorocarbon manufacturing pro-cess patents that further protect the perfluorocarbons with which we are working.

Biosensor: Through SYBD’s IBS division, the company has three issued U.S. biosensor patents (5,914,026; 5,964,993;6,343,225) and one Australian patent (720712) that protect important design features of our implanted glucose biosensor and other biosensor applications, both medical and industrial. SYBD has also exclusively licensed three fundamental biosensor patents issued to Dr. Clark and assigned to Children’s Hospital in Cincinnati.

For all U.S. patents and applications, the company also submits applications and pursues patents in Europe, Canada, Japan, and Australia. SYBD therefore has a number of foreign perfluorocarbon and biosensor patent applications submitted and pending.

All patents assigned to SYBD or IBS are the sole intellectual property of the company.